Format

Send to

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2008 Jul;14(6):759-63. doi: 10.1177/1352458507088105. Epub 2008 May 27.

Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.

Author information

  • 1Department of Neurology, Baird MS Center, Jacobs Neurological Institute, Buffalo, NY 14203, USA. zs2@buffalo.edu

Abstract

OBJECTIVES:

To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS).

METHOD:

37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA).

RESULTS:

Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls (p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts (p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed (p = 0.012).

CONCLUSION:

The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.

PMID:
18505774
DOI:
10.1177/1352458507088105
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center